Catalent (NYSE:CTLT) Downgraded to Sell Rating by StockNews.com

Catalent (NYSE:CTLT) was downgraded by analysts at StockNews.com from a “hold” rating to a “sell” rating in a note issued to investors on Friday.

A number of other research analysts have also weighed in on CTLT. William Blair reiterated a “market perform” rating on shares of Catalent in a research note on Tuesday, September 3rd. Robert W. Baird restated a “neutral” rating and set a $63.50 price target on shares of Catalent in a research report on Tuesday, September 24th. Finally, Baird R W lowered shares of Catalent from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 24th. One investment analyst has rated the stock with a sell rating and seven have given a hold rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $63.40.

Catalent Stock Up 1.1 %

Catalent stock opened at $59.66 on Friday. Catalent has a 1-year low of $36.74 and a 1-year high of $61.20. The firm has a market capitalization of $10.83 billion, a price-to-earnings ratio of -26.40, a P/E/G ratio of 2.34 and a beta of 1.16. The company has a current ratio of 2.51, a quick ratio of 1.96 and a debt-to-equity ratio of 1.38. The firm has a 50 day simple moving average of $59.79 and a 200 day simple moving average of $58.25.

Catalent (NYSE:CTLT) last released its quarterly earnings data on Tuesday, November 5th. The company reported ($0.13) earnings per share for the quarter, missing analysts’ consensus estimates of $0.05 by ($0.18). Catalent had a negative net margin of 9.28% and a negative return on equity of 0.66%. The business had revenue of $1.02 billion during the quarter, compared to analysts’ expectations of $1.06 billion. During the same quarter in the prior year, the firm posted ($0.10) earnings per share. The firm’s quarterly revenue was up 4.2% on a year-over-year basis. On average, analysts predict that Catalent will post 0.84 earnings per share for the current year.

Insider Activity

In other news, insider David Mcerlane sold 1,994 shares of Catalent stock in a transaction on Thursday, September 26th. The shares were sold at an average price of $59.97, for a total transaction of $119,580.18. Following the completion of the sale, the insider now directly owns 36,304 shares of the company’s stock, valued at approximately $2,177,150.88. The trade was a 5.21 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Michelle R. Ryan sold 2,800 shares of Catalent stock in a transaction on Monday, November 11th. The stock was sold at an average price of $59.70, for a total transaction of $167,160.00. Following the sale, the director now directly owns 10,835 shares of the company’s stock, valued at $646,849.50. This represents a 20.54 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 5,114 shares of company stock worth $305,931 in the last three months. Corporate insiders own 0.31% of the company’s stock.

Institutional Trading of Catalent

A number of hedge funds have recently made changes to their positions in the stock. Neo Ivy Capital Management bought a new stake in Catalent in the third quarter worth $1,078,000. Nomura Asset Management Co. Ltd. lifted its stake in Catalent by 1.4% in the third quarter. Nomura Asset Management Co. Ltd. now owns 53,011 shares of the company’s stock worth $3,211,000 after purchasing an additional 750 shares during the last quarter. National Bank of Canada FI lifted its stake in Catalent by 300.0% in the third quarter. National Bank of Canada FI now owns 1,460,813 shares of the company’s stock worth $88,481,000 after purchasing an additional 1,095,578 shares during the last quarter. State Street Corp lifted its stake in Catalent by 1.5% in the third quarter. State Street Corp now owns 7,451,135 shares of the company’s stock worth $451,315,000 after purchasing an additional 113,095 shares during the last quarter. Finally, Quantinno Capital Management LP lifted its stake in Catalent by 30.6% in the third quarter. Quantinno Capital Management LP now owns 16,290 shares of the company’s stock worth $987,000 after purchasing an additional 3,817 shares during the last quarter.

About Catalent

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.